These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 22978385)

  • 1. The metabolic and toxicological considerations for immunosuppressive drugs used during pancreas transplantation.
    Rangel EB
    Expert Opin Drug Metab Toxicol; 2012 Dec; 8(12):1531-48. PubMed ID: 22978385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tacrolimus in pancreas transplant: a focus on toxicity, diabetogenic effect and drug-drug interactions.
    Rangel EB
    Expert Opin Drug Metab Toxicol; 2014 Nov; 10(11):1585-605. PubMed ID: 25255841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. mTOR inhibitors in pancreas transplant: adverse effects and drug-drug interactions.
    Fernandes-Silva G; Ivani de Paula M; Rangel ÉB
    Expert Opin Drug Metab Toxicol; 2017 Apr; 13(4):367-385. PubMed ID: 27659512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Everolimus with reduced-dose cyclosporine versus full-dose cyclosporine and mycophenolate in de novo renal transplant patients: a 2-year single-center experience.
    Santos SM; Carlos CM; Cabanayan-Casasola CB; Danguilan RA
    Transplant Proc; 2012 Jan; 44(1):154-60. PubMed ID: 22310603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mycophenolate mofetil-based immunosuppressive minimization and withdrawal strategies in renal transplantation: possible risks and benefits.
    Meier-Kriesche HU
    Curr Opin Nephrol Hypertens; 2006 Jun; 15 Suppl 1():S1-5. PubMed ID: 16829733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Minimization of maintenance immunosuppression early after renal transplantation: an interim analysis.
    Bemelman FJ; de Maar EF; Press RR; van Kan HJ; ten Berge IJ; Homan van der Heide JJ; de Fijter HW
    Transplantation; 2009 Aug; 88(3):421-8. PubMed ID: 19667948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Minimization protocols in pancreas transplantation.
    Cantarovich D; Vistoli F
    Transpl Int; 2009 Jan; 22(1):61-8. PubMed ID: 18713147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential therapeutic interventions to avoid or treat chronic allograft dysfunction.
    Kahan BD
    Transplantation; 2001 Jun; 71(11 Suppl):SS52-7. PubMed ID: 11583490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Minimization and withdrawal of steroids in pancreas and islet transplantation.
    Mineo D; Sageshima J; Burke GW; Ricordi C
    Transpl Int; 2009 Jan; 22(1):20-37. PubMed ID: 18855850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Considerations in sirolimus use in the early and late post-transplant periods.
    Patel SJ; Elliott EN; Knight RJ; Gaber LW; Gaber AO
    Expert Opin Drug Saf; 2009 Jul; 8(4):421-34. PubMed ID: 19522662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of different long-term maintenance immunosuppressive therapy strategies on patients' outcome after heart transplantation.
    Dandel M; Lehmkuhl HB; Knosalla C; Hetzer R
    Transpl Immunol; 2010 Jul; 23(3):93-103. PubMed ID: 20434559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conversion to sirolimus for chronic allograft nephropathy and calcineurin inhibitor toxicity and the adverse effects of sirolimus after conversion.
    Sayin B; Karakayali H; Colak T; Sevmis S; Pehlivan S; Demirhan B; Haberal M
    Transplant Proc; 2009 Sep; 41(7):2789-93. PubMed ID: 19765436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A drug safety evaluation of everolimus in kidney transplantation.
    Holdaas H; Midtvedt K; Åsberg A
    Expert Opin Drug Saf; 2012 Nov; 11(6):1013-22. PubMed ID: 22954349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is acute rejection the key predictor for long-term outcomes after renal transplantation when comparing calcineurin inhibitors?
    Nashan B
    Transplant Rev (Orlando); 2009 Jan; 23(1):47-52. PubMed ID: 19027616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comprehensive update of the metabolic and toxicological considerations for immunosuppressive drugs used during pancreas transplantation.
    Vidigal AC; de Lucena DD; Beyerstedt S; Rangel ÉB
    Expert Opin Drug Metab Toxicol; 2023; 19(7):405-427. PubMed ID: 37542452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
    Bumbea V; Kamar N; Ribes D; Esposito L; Modesto A; Guitard J; Nasou G; Durand D; Rostaing L
    Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Obesity, metabolic syndrome and diabetes mellitus after renal transplantation: prevention and treatment.
    Wissing KM; Pipeleers L
    Transplant Rev (Orlando); 2014 Apr; 28(2):37-46. PubMed ID: 24507957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early sirolimus therapy in renal transplant recipients at high risk: is it justified?
    Halim MA; Al-Otaibi T; Johny KV; Hamid MH; Al-Waheeb S; Hasaneen H; Awadain WH; Nawas KM; El-Sayed A; Said T; Nair MP; Nampoory MR
    Transplant Proc; 2009 Sep; 41(7):2784-8. PubMed ID: 19765435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sirolimus-based triple immunosupression with antithymocyte globulin induction in expanded criteria donor kidney transplantation.
    Uslu A; Nart A; Taşli FA; Postaci H; Aykas A; Doğan M; Sahin T
    Nephrology (Carlton); 2008 Feb; 13(1):80-6. PubMed ID: 18199109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Experience with steroid-free maintenance immunosuppression in simultaneous pancreas-kidney transplantation.
    Freise CE; Kang SM; Feng S; Posselt A; Hirose K; Hirose R; Stock P
    Transplant Proc; 2004 May; 36(4):1067-8. PubMed ID: 15194370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.